StemCells, Inc. (Nasdaq:STEM) announced today that its president and CEO, Martin McGlynn, is featured on the financial website www.wallstreetreporter.com.
In an interview, Mr. McGlynn discussed the Company's recent dosing of the first patient in the Company's Phase I/II clinical trial in chronic spinal cord injury, the Company's efforts to develop its proprietary HuCNS-SC® cells for a range of central nervous system disorders, its other business activities, and its management team. Mr. McGlynn's interview can be accessed online at http://www.wallstreetreporter.com/2011/09/stemcells-inc-nasdaqstem-ceo-interview/.
The Wall Street Reporter is an established and important information source for public companies. The interview will be available to their global investor audience, which includes fund managers, stockbrokers, analysts, and investment bankers, as well as sophisticated individual investors.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. In addition, the Company plans to file an IND by year-end 2011 to initiate a clinical trial of HuCNS-SC cells in the dry form of age-related macular degeneration, and is also pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease and stroke. StemCells also markets stem cell research products including media and reagents, under the SC Proven®brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.